Hannah Jergas
Overview
Explore the profile of Hannah Jergas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
126
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jergas H, Steffen J, Schedlich-Teufer C, Strelow J, Kramme J, Fink G, et al.
Brain Sci
. 2024 Sep;
14(9).
PMID: 39335409
Deep brain stimulation (DBS) for Parkinson's disease (PD) often necessitates frequent clinic visits for stimulation program optimization, with limited experience in remote patient management. Due to the resource-intensive nature of...
2.
Jergas H, Petry-Schmelzer J, Hannemann J, Thies T, Strelow J, Rubi-Fessen I, et al.
J Neurol Neurosurg Psychiatry
. 2024 Aug;
PMID: 39147574
Background: Stimulation-induced dysarthria (SID) is a troublesome and potentially therapy-limiting side effect of deep brain stimulation of the subthalamic nucleus (STN-DBS) in patients with Parkinson's disease (PD). To date, the...
3.
Thies T, Jergas H, Mucke D, Brandt G, Visser-Vandewalle V, Pinto S, et al.
Brain Stimul
. 2024 Jan;
16(6):1598-1600.
PMID: 38193255
No abstract available.
4.
Purner D, Hormozi M, Weiss D, Barbe M, Jergas H, Prell T, et al.
Neurology
. 2023 Nov;
101(21):e2078-e2093.
PMID: 37914414
Background And Objectives: Advanced therapies (ATs; deep brain stimulation [DBS] or pump therapies: continuous subcutaneous apomorphine infusion [CSAI], levodopa/carbidopa intestinal gel [LCIG]) are used in later stages of Parkinson disease...
5.
van der Linden C, Berger T, Brandt G, Strelow J, Jergas H, Baldermann J, et al.
Sensors (Basel)
. 2023 Oct;
23(20).
PMID: 37896714
Clinical rating scales for tremors have significant limitations due to low resolution, high rater dependency, and lack of applicability in outpatient settings. Reliable, quantitative approaches for assessing tremor severity are...
6.
Brinke T, Jergas H, Sisodia V, Barbe M, Odekerken V, Verbaan D, et al.
BMC Neurol
. 2023 Oct;
23(1):372.
PMID: 37853327
Background: The effectiveness of Deep Brain Stimulation (DBS) therapy for Parkinson's disease can be limited by side-effects caused by electrical current spillover into structures adjacent to the target area. The...
7.
Jergas H, Baldermann J, Wirths J, Barbe M, Visser-Vandewalle V, Andrade P
Surg Neurol Int
. 2023 Mar;
14:24.
PMID: 36895223
Background: Hyperkinetic movement disorders secondary to brain tissue damage due to hyperglycemia are a rare complication of diabetes mellitus. Nonketotic hyperglycemic hemichorea (NH-HC) is characterized by a rapid onset of...
8.
Schaffrath A, Schleyken S, Seger A, Jergas H, Ozduzenciler P, Pils M, et al.
NPJ Parkinsons Dis
. 2023 Feb;
9(1):14.
PMID: 36732520
Misfolded and aggregated α-synuclein is a neuropathological hallmark of Parkinson's disease (PD). Thus, α-synuclein aggregates are regarded as a biomarker for the development of diagnostic assays. Quantification of α-synuclein aggregates...
9.
Strelow J, Dembek T, Baldermann J, Andrade P, Jergas H, Visser-Vandewalle V, et al.
Brain Sci
. 2022 Dec;
12(12).
PMID: 36552185
Intra- and perioperatively recorded local field potential (LFP) activity of the nucleus subthalamicus (STN) has been suggested to guide contact selection in patients undergoing deep brain stimulation (DBS) for Parkinson's...
10.
Petry-Schmelzer J, Gerus L, Jergas H, Reker P, Steffen J, Dafsari H, et al.
J Parkinsons Dis
. 2022 May;
12(5):1497-1505.
PMID: 35491797
Background: Subthalamic nucleus deep brain stimulation (STN-DBS) is a well-established treatment for patients with Parkinson's disease. Previous acute challenge studies suggested that short pulse widths might increase the therapeutic window...